Keywords: schering-plough, commences, phase, iii, enzon, peg-intron, rebetol
Schering-Plough commences Phase III with Enzon's PEG-Intron and Rebetol
Article | 04 February 1999
- Schering-Plough has commenced Phase III trials for combinationtherapy of Enzon's PEG-Intron (PEG-interferon alfa-2b) and Rebetol (ribavirin) for the treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
